Intersect ENT, Inc., a commercial stage drug-device company committed to improving the quality of life for patients with ear, nose and throat conditions, today announced the appointment of Jeryl Hilleman as chief financial officer. Ms. Hilleman brings significant financial and executive experience to Intersect ENT, having served as chief financial officer for several publicly traded life science and clean technology companies.
"I am thrilled to welcome Jeri to our team," said Lisa Earnhardt, president and chief executive officer of Intersect ENT. "She is an accomplished executive with substantial experience in growth and scaling that will be valuable to Intersect ENT as we seek to expand our commercial capabilities as well as our product offerings to provide chronic sinus sufferers and their physicians access to our proprietary local drug delivery technology.”
“This is a unique opportunity to join a dynamic and innovative team that is making patients’ lives better every day and has multiple areas of opportunity for growth and expansion. I am excited to work with Lisa and the board to continue to build the company’s business,” said Ms. Hilleman.
Ms. Hilleman has over two decades of experience as CFO of both private and public companies, including overseeing four initial public offerings and a reverse merger. Most recently, Ms. Hilleman served as CFO of Ocera Therapeutics (Nasdaq: OCRX), a clinical-stage biotech company focused on treatment of liver disorders. From 2008 to 2012, Ms. Hilleman served as CFO of Amyris, Inc. (Nasdaq: AMRS), a multi-national renewable products company based in California and Brazil. Prior to Amyris, Ms. Hilleman served as CFO of Symyx Technologies (Nasdaq: ACCL), a company selling instruments, software and research services to pharmaceutical and chemical companies. In addition, Ms. Hilleman led the finance function at two public biotechnology companies, Geron Corporation (Nasdaq: GERN) and Cytel Corporation (formerly Nasdaq: CYTL). Ms. Hilleman is also a member of the board of directors and chair of the audit committee of Xenoport (Nasdaq: XNPT), a biopharmaceutical company focused on the treatment of neurological disorders. Ms. Hilleman holds an A.B. from Brown University and an M.B.A. from the Wharton Graduate School of Business.
In addition to her financial duties, Ms. Hilleman will also lead the company’s business development, human resources and legal functions, joining Monika De Martini, who has already built an outstanding team.
About Intersect ENT
Intersect ENT, Inc. is a commercial stage drug-device company committed to improving the quality of life for patients with ear, nose and throat conditions. Intersect ENT’s drug-eluting bioabsorbable implant technology enables targeted and sustained release of therapeutic agents. Intersect ENT’s initial products, PROPEL and PROPEL mini, are the first and only drug-eluting implants approved for use in patients with chronic sinusitis. Use of the PROPEL implants is clinically proven to improve surgical outcomes by maintaining the open pathways created in surgery and reducing the need for oral steroids and additional surgical procedures. In addition, Intersect ENT is developing new, less invasive and more cost-effective drug-eluting bioabsorbable treatment options for the management of chronic sinusitis in the physician office setting to provide benefits for patients, physicians and payors.